Exciting News: A New Osteoporosis Drug Approved by NICE

At MenoHealth, we’re always on the lookout for new developments that can make a positive impact on women’s health, especially during and after menopause. That’s why we’re pleased to share some promising news: The National Institute for Health and Care Excellence (NICE) has just approved a new osteoporosis drug called Abaloparatide for use by the NHS in England which could be a game-changer for some. But don’t get too excited as this isn’t suitable or available to everyone – read on to find out more.

What is Abaloparatide?

Abaloparatide, also known by its brand name Eladynos and made by Theramex, is a medication designed to increase bone density by stimulating the cells responsible for creating new bone. This is crucial for women who have gone through menopause, as the drop in oestrogen levels during this time can lead to a reduction in bone density, increasing the risk of osteoporosis—a condition that causes bones to become thin and brittle, making fractures more likely.

Who Can Benefit?

NICE estimates that more than 14,000 women who have gone through menopause and are at high risk of fractures could benefit from Abaloparatide. This new osteoporosis drug is a particularly good option for those who haven’t responded well to or cannot tolerate the usual treatments, which often include romosozumab or teriparatide, followed by bisphosphonates like alendronic acid.

A Convenient New Option

Abaloparatide comes in a pre-filled pen that’s injected into the muscle through the skin, meaning it can be self-administered at home making it far more convenient for many.

Why This Matters

Fractures due to osteoporosis can be incredibly painful and affect independence and quality of life so preventing them is crucial. Abaloparatide provides a new option which should be available on the NHS within the next three months.

What’s Next?

If you think you might be eligible for this new treatment, it’s worth having a conversation with your GP or specialist. They can provide more information on whether Abaloparatide could be right for you and discuss the best course of action to protect your bone health.

At MenoHealth, we’re committed to keeping you informed about the latest in menopause care and support. If you have any questions or want to learn more about managing menopause and beyond, don’t hesitate to reach out or join one of our sessions. Although we can’t give medical advice, we can point you in the right direction. Together, we can take control of our health and well-being at every stage of life.